Using Aprepitant for Kids with Cyclical Vomiting Syndrome
Author Information
Author(s): Thavamani Aravind, Malay Sindhoosha, Khatana Jasmine, Velayuthan Sujithra, Sankararaman Senthilkumar, Losurdo Giuseppe
Primary Institution: Case Western Reserve University School of Medicine
Hypothesis
Aprepitant use may be associated with a decrease in the 7-day readmission rate.
Conclusion
Aprepitant use as an abortive therapy did not affect the 7-day CVS-related readmission rate.
Supporting Evidence
- The aprepitant group had a longer hospital stay and higher costs.
- There were no significant differences in readmission rates at 7, 14, or 30 days.
- Patients receiving aprepitant had higher readmission rates at 90, 180, and 365 days, but these were not statistically significant.
Takeaway
This study looked at kids with a sickness that makes them throw up a lot. It found that a medicine called aprepitant didn't help them stay out of the hospital any better than other treatments.
Methodology
Analyzed pediatric patients with CVS using the Pediatric Health Information System database, comparing those who received aprepitant with those who did not.
Potential Biases
Referral bias may have been introduced as the data was collected from tertiary care hospitals, which may see more severe cases.
Limitations
The study could not determine the timing, frequency, and dosage of aprepitant use, and relied on ICD coding which may have inaccuracies.
Participant Demographics
Pediatric patients under 18 years old, with a primary diagnosis of CVS, analyzed from 2016 to 2019.
Statistical Information
P-Value
0.91
Statistical Significance
p = 0.91
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website